In order to evaluate the biocompatibility profile of a newly designed peritoneal dialysis fluid (PDF), we evaluated peritoneal leukocyte (PMΦ) cytokine release following overnight in vivo dwells using standard, lactate-buffered, single-chamber bag PDF (Lac-PDF) and purely bicarbonate-buffered, double-chamber bag PDF containing 34 (Bic-PDF) or 39 (Bic Hi-PDF) mmol/L bicarbonate.
Design
A randomized, open, crossover clinical trial with single weekly test dwells was performed in stable, long-term continuous ambulatory PD patients (n = 8). During 8-hour overnight dwells, PMΦ were exposed to different PDF containing 1.5% glucose. After drainage, peritoneal cells were isolated and incubated with RPMI 1640 medium for 2 or 3 hours, with and without stimulation by lipopolysaccharide (LPS). Ex vivo release of tumor necrosis factor (TNF)-α and interleukin (IL)-6 was measured by specific ELISA technique.
Results
After pre-exposure to Lac-PDF, PMΦ generated 242 ± 279 pg TNFα/106 cells and 157 ± 105 pg IL-6/106 cells. When pre-exposed to Bic-PDF and Bic Hi-PDF, TNFα and IL-6 production of PMΦ was not significantly different from Lac-PDF. After LPS stimulation (100 ng/mL), PMΦ secretion of TNFα and IL-6 pre-exposed to three PDF revealed no significant differences between groups: TNFα was 2864 ± 1216, 2910 ± 1202, and 3291 ± 558 pg/106 cells after overnight dwells with Lac-PDF, Bic-PDF, and Bic Hi-PDF, respectively. Comparably, LPS-stimulated (100 pg/mL) PMΦ showed IL-6 secretion of 891 ± 335, 1380 ± 1149, and 1442 ± 966 pg/106 cells for Lac-PDF, Bic-PDF, and Bic Hi-PDF.
Conclusion
After long-term overnight dwells, initial pH, the different buffers, and varying glucose degradation product levels of PDF do not strongly affect PMΦ function with respect to cytokine release. The lack of significant differences between fluids may result from the complete dialysate equilibration achieved during the overnight intraperitoneal dwell.
HarrisD.C.H., YuillE.J., BythK., ChapmanJ.R., HuntC.Twin- versus single-bag disconnect systems: Infection rates and cost of continuous ambulatory peritoneal dialysis.J Am Soc Nephrol1996; 7: 2392–8.
2.
MaiorcaR., CancariniG., BroccoliR., BrasaS., CanteluppiA., ScalamognaA.Prospective control trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis.Lancet1983; 2: 642.
3.
RutkowskiB., Lichodziejewska–NiemierkoM., LiberekT., RenkeM., Bielinska–OgrodnikD.Peritoneal dialysis in Poland. Part 2. Individualisation of the therapy, complications, outcome (in Polish).Nefrol Dial Pol1997; 1: 186–90.
4.
WaradyB.A., SullivanE.K., AlexanderS.R.Lessons from the peritoneal dialysis patient database: A report of the North American Pediatric Renal Transplant Cooperative Study.Kidney Int Suppl1996; 56: S68–71.
5.
SpinelliC., d'AdamoG., BalducciA., VentolaF.R., PolitoP., RuggieriG.Indications and adequacy of automated peritoneal dialysis in 74 patients.Adv Perit Dial1991; 7: 51–3.
6.
DaviesS.J., PhillipsL., GriffithsA.M., RussellL.H., NaishP.F., RussellG.I.What really happens to people on long-term peritoneal dialysis?Kidney Int1998; 57: 2207–17.
7.
MaiorcaR., VoneshE., CavalliP.L., De VecchiA., GiangrandeA., La GrecaG.A multicenter, selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis.Perit Dial Int1991; 11: 118–27.
8.
LupoA., TarchiniR., CancariniG.C., CatizoneL., CocchiR., De VecchiA.Long-term outcome in continuous ambulatory peritoneal dialysis: 10 year survey by the Italian Cooperative Peritoneal Dialysis Study Group.Am J Kidney Dis1994; 24: 826–37.
9.
MaiorcaR., CancariniG.C., ZubaniR., CameriniC., ManiliM., BrunoriG.CAPD viability: A long term comparison with hemodialysis.Perit Dial Int1996; 16: 276–87.
10.
JörresA., GahlG.M., FreiU.Peritoneal dialysis fluid biocompatibility: Does it really matter?Kidney Int Suppl1994; 48: S79–86.
11.
TopleyN.Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions.Adv Ren Replace Ther1998; 5: 179–84.
12.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
LageC., PischetsriederM., AufrichtC., JörresA., SchillingH., Passlick–DeetjenJ.First in vitro and in vivo experiences with Stay·Safe Balance, a pH-neutral solution in a dual-chambered bag.Perit Dial Int2000; 20(Suppl 5): S28–32.
15.
WitowskiJ., KorybalskaK., WisniewskaJ., BreborowiczA., GahlG.M., FreiU.Effects of glucose degradation products on human peritoneal mesothelial cell function.J Am Soc Nephrol2000; 11: 729–39.
16.
TauerA., KnerrT., NiwaT., SchaubT.P., LageC., Passlick–DeetjenJ.In vitro formation of N-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis.Biochem Biophys Res Commun2001; 280: 1408–14.
DaviesS.J., BryanJ., PhillipsL., RussellG.I.Longitudinal changes in peritoneal kinetics: The effect of peritoneal dialysis and peritonitis.Nephrol Dial Transplant1996; 11: 498–506.
19.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.J Am Soc Nephrol2001; 12: 1046–51.
20.
TopleyN., KaurD., PetersenM.M., JörresA., Passlick–DeetjenJ., ColesG.A.Bio-compatibility of bicarbonate-buffered peritoneal dialysis fluids: Influence on mesothelial cell and neutrophil function.Kidney Int1996; 49: 1447–65.
21.
TopleyN., KaurD., JörresA., Passlick–DeetjenJ., ColesG., WilliamsJ.D.Human peritoneal mesothelial cell (HPMC) viability and cytokine synthesis in bicarbonate vs lactate peritoneal dialysis fluids (PDF) (Abstract).J Am Soc Nephrol1994; 5: 481.
22.
JörresA., GahlG.M., TopleyN., NeubauerA., LudatK., MüllerC.In vitro biocompatibility of alternative CAPD fluids: Comparison of bicarbonate-buffered and glucose-polymer-based solutions.Nephrol Dial Transplant1994; 9: 785–90.
LiberekT., TopleyN., MistryC.D., ColesG.A., MorganT., QuirkR.A.Cell function and viability in glucose polymer peritoneal dialysis fluids.Perit Dial Int1993; 13: 104–11.
25.
LiberekT., TopleyN., JörresA., ColesG.A., GahlG.M., WilliamsJ.D.Peritoneal dialysis fluid inhibition of phagocyte function: Effects of osmolality and glucose concentration.J Am Soc Nephrol1993; 3: 1508–15.
26.
LiberekT., TopleyN., JörresA., PetersenM.M., ColesG.A., GahlG.M.Peritoneal dialysis fluid inhibition of neutrophil (PMN) respiratory burst activation is related to the lowering of intracellular pH [pH]i.Nephron1993; 65: 260–5.
27.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
28.
DobbieJ.W., AndersonJ.W., HindC.Long term effects of peritoneal dialysis on peritoneal morphology.Perit Dial Int1994; 14(Suppl 3): S16–20.
29.
FallerB., LameireN.Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years.Nephrol Dial Transplant1994; 9: 280–6.
30.
FerianiM., BiasioliS., BorinD., BrendolanA., GargantiniL., ChiaramonteS.Bicarbonate solutions for peritoneal dialysis: A reality.Int J Artif Organs1985; 8: 57–8.
31.
FerianiM., DissegnaD., La GrecaG., Passlick–DeetjenJ.Short-term clinical study with bicarbonate-containing peritoneal dialysis solution.Perit Dial Int1993; 13: 296–301.
32.
FerianiM., CarobiC., La GrecaG., BuoncristianiU., Passlick–DeetjenJ.Clinical experience with 39 mmol/L bicarbonate-buffered peritoneal dialysis solution.Perit Dial Int1997; 17: 17–21.
33.
FerianiM., KirchgessnerJ., La GrecaG., Passlick–DeetjenJ., and the Bicarbonate CAPD Cooperative Group. Randomized long-term evaluation of bicarbonate-buffered CAPD solution.Kidney Int1998; 54: 1731–8.
34.
SteinA., BakerF., LarrattC., BennettS., HarrisK., FeehallyJ.Correction of metabolic acidosis and the protein catabolic rate in PD patients.Perit Dial Int1994; 14: 187–9.
35.
GrahamK.A., ReaichD., ChannonS.M., DownieS., GilmourE., Passlick–DeetjenJ.Correction of acidosis in CAPD decreases whole body protein degradation.Kidney Int1996; 49: 1396–400.
36.
TopleyN.What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions?Perit Dial Int1995; 15: 205–9.
37.
de FijterC., VerbrughH., PetersE., OeP.L., Van der MeulenJ., VerhoefJ.In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.Clin Nephrol1993; 39: 75–80.
38.
de FijterC., VerbrughH., OeP.L., HeeziusE., VerhoefJ., DonkerA.Antibacterial peritoneal defence in automated peritoneal dialysis: Advantages of tidal over continuous cyclic peritoneal dialysis?Nephrol Dial Transplant1994; 9: 156–62.
39.
MackenzieR.K., HolmesC.J., MosleyA., JenkinsJ.P., WilliamsJ.D., ColesG.A.Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFα secretion.J Am Soc Nephrol1998; 9: 1499–506.
40.
MackenzieR.K., JonesS., MosleyA., HolmesC.J., ArgyleR., WilliamsJ.D.In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function.Am J Kidney Dis2000; 35: 112–21.
41.
MahioutA., MatataB.M., BrunkhorstR.Effect of glucose and pyruvate in acidic and non-acidic peritoneal dialysis fluids on leukocytes cell functions.Kidney Int1997; 51: 860–7.
42.
RogachevB., HausmannM.J., YulzariR., WeilerM., HolmesC., FaictD.Effect of bicarbonate-based dialysis solutions on intracellular pH (pHi) and TNFα production by peritoneal macrophages.Perit Dial Int1997; 17: 546–53.
43.
DouvdevaniA., RapaportJ., KonfortyA., YulzariR., MoranA., ChaimovitzC.Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages.J Am Soc Nephrol1995; 6: 207–13.
